Synthroid (Levothyroxine): Dosing, Side Effects, and How It Compares to T3 and Desiccated Thyroid

What Is Levothyroxine and Why Is It the Standard of Care?

Levothyroxine is synthetic thyroxine (T4), the same hormone the healthy thyroid gland secretes in highest volume. It has been the dominant hypothyroidism treatment since the 1960s and remains the preferred drug in the 2014 American Thyroid Association (ATA) guidelines and the 2019 European Thyroid Association (ETA) recommendations. [1][2]

The pharmacological rationale is straightforward. Circulating T4 converts to the biologically active triiodothyronine (T3) in peripheral tissues, particularly the liver and kidney, through the enzyme deiodinase. This conversion means a single daily T4 dose produces a relatively stable, smooth supply of active hormone over time. The long serum half-life of levothyroxine (approximately 7 days) means small missed doses rarely cause symptomatic swings, which aids adherence compared to shorter-acting agents.

The 2014 ATA guideline states directly: "Levothyroxine (T4) monotherapy is the standard of care for hypothyroidism." [1] Three large systematic reviews, including a 2012 Cochrane analysis examining nine randomized controlled trials, found no consistent quality-of-life advantage for combination T4 plus T3 over T4 alone in the general hypothyroid population. [3]

Approved indications include primary hypothyroidism from any cause (Hashimoto thyroiditis, post-thyroidectomy, radioiodine ablation, congenital hypothyroidism), secondary hypothyroidism due to pituitary disease, and TSH suppression therapy in well-differentiated thyroid cancer. Levothyroxine is FDA-approved under multiple brand names including Synthroid, Levoxyl, Tirosint, and Unithroid. [4]

How Levothyroxine Is Dosed: Starting, Titrating, and Monitoring

Dosing starts at body weight. The full replacement dose for most adults with primary hypothyroidism is 1.6 mcg per kg of actual body weight per day. [1] A 75 kg adult, therefore, typically requires approximately 125 mcg daily.

Age and cardiac status modify this number. Adults over 65 or those with known cardiovascular disease typically begin at 25 mcg daily, with increases of 12.5 to 25 mcg every 4 to 6 weeks. Patients with subclinical hypothyroidism (elevated TSH with normal free T4 and no symptoms) may need lower doses, sometimes 50 to 75 mcg. Pregnant women require roughly 30% more levothyroxine than pre-pregnancy, and the dose should be adjusted at confirmed pregnancy. [1]

TSH is the primary monitoring marker. After any dose initiation or change, TSH should be re-checked at 4 to 6 weeks, because the 7-day half-life means steady-state takes about five to six half-lives to reach. For most non-pregnant adults, the target TSH is 0.4 to 4.0 mIU/L. The ATA recommends a narrower target of 0.5 to 2.5 mIU/L for pregnant women in the first trimester. [1]

Free T4 is measured alongside TSH when central (pituitary) hypothyroidism is suspected, because TSH alone will be misleadingly low in that setting. Free T3 is not routinely required for monitoring pure levothyroxine therapy, though it becomes relevant when assessing combination regimens.

Synthroid vs. Tirosint: Does the Formulation Matter?

Tirosint (levothyroxine gelatin soft capsule) and Tirosint-SOL (liquid solution) differ from conventional tablet formulations in one key way. They contain no acacia, lactose, dyes, or gluten. [5]

This matters clinically in specific populations. Patients with atrophic gastritis, celiac disease, inflammatory bowel disease, or lactose intolerance may absorb tablet levothyroxine erratically. A 2013 study published in the Journal of Clinical Endocrinology and Metabolism (N=36) showed that liquid levothyroxine produced significantly better TSH normalization than tablets in patients with gastric acid-related malabsorption, with TSH reaching target in 87% of the liquid group versus 44% of the tablet group. [6]

Tirosint is also the preferred formulation when patients cannot swallow pills, such as infants with congenital hypothyroidism or adults recovering from bariatric surgery. The dose is identical to the tablet dose; switching formulations requires a TSH recheck at 6 weeks because bioavailability differences may alter TSH by a clinically relevant margin.

One practical caveat: Tirosint costs significantly more than generic levothyroxine tablets. When cost is a barrier, crushing a tablet and dissolving it in water is a reasonable short-term workaround, though it is less precise than Tirosint-SOL.

Liothyronine (Cytomel): When T3 Therapy Makes Sense

Liothyronine is synthetic T3, the biologically active thyroid hormone that binds directly to nuclear receptors. Unlike T4, it does not require peripheral conversion. That makes it faster-acting and more potent on a microgram-per-microgram basis, but it also creates a short half-life of roughly 24 hours, which leads to peak-and-trough hormone fluctuations when given once daily. [7]

The clinical indications for liothyronine are narrower than those for levothyroxine. The ATA and ETA identify four situations where T3 addition may be considered: persistent symptoms despite optimized TSH on T4 monotherapy, genetic variants in the DIO2 gene (which encodes the deiodinase enzyme responsible for T4-to-T3 conversion), low free T3 levels despite normal TSH, and patient preference after an informed discussion of the evidence. [2]

A 2019 ETA meta-analysis of combination T4+T3 trials found that approximately 49% of hypothyroid patients preferred combination therapy when given a choice in crossover studies, even though objective markers such as weight and mood did not consistently favor combination treatment. [2] This preference gap is real and clinically worth acknowledging in shared decision-making.

Typical liothyronine doses range from 5 to 25 mcg per day, usually split into two doses to blunt the peak. Many endocrinologists use a T4:T3 ratio of roughly 13:1 to 20:1 when constructing combination regimens, partially replacing some levothyroxine with liothyronine. [2]

Liothyronine carries specific cardiovascular caution. The increased T3 bioavailability raises resting heart rate and may worsen atrial fibrillation risk in susceptible patients. It is generally avoided or used with close cardiac monitoring in adults over 60 with known arrhythmia history. [7]

Armour Thyroid and NP Thyroid: The Desiccated Thyroid Option

Desiccated thyroid extract (DTE) is dried, powdered porcine (pig) thyroid gland. Armour Thyroid (Forest/Allergan) and NP Thyroid (Acella Pharmaceuticals) are the two most commonly prescribed brands in the United States. Both contain T4 and T3 in a fixed ratio of approximately 4:1 by weight, meaning a 60 mg (1 grain) tablet provides roughly 38 mcg T4 and 9 mcg T3. [8]

That built-in T3 is both the appeal and the limitation of DTE. Patients who feel better on DTE often attribute it to the T3 content. Controlled trial data on whether DTE outperforms levothyroxine for subjective wellbeing are sparse. A 2013 randomized crossover trial by Hoang et al. (N=70) published in the Journal of Clinical Endocrinology and Metabolism found that 49% of participants preferred DTE over levothyroxine, with associated reductions in body weight (averaging 3 lb more loss on DTE) and modest improvements on cognitive testing. [9] Limitations of that study include small sample size and a single-center design.

DTE dosing is expressed in grains or milligrams. A standard starting dose is 30 mg (0.5 grain) once daily, titrated upward every 4 to 6 weeks by TSH and symptom response. Most patients stabilize between 60 and 120 mg per day. Because DTE contains T3, TSH suppression below normal is common at doses that adequately relieve symptoms, and the clinical interpretation of TSH on DTE differs from pure T4 therapy. Free T3 should be monitored alongside TSH in DTE patients. [8]

One supply-chain concern: NP Thyroid experienced voluntary recalls in 2019 due to super-potency (higher-than-labeled hormone content), and Armour Thyroid experienced intermittent shortages. [10] Patients who stabilize on DTE should have a contingency plan with their prescriber if their brand becomes unavailable.

Choosing Between Levothyroxine, Combination T4+T3, and Desiccated Thyroid: A Decision Framework

The right thyroid regimen is not the same for every patient. The table below outlines the four most common clinical situations and the regimen most supported by current evidence.

Situation 1: New hypothyroid diagnosis, no complicating factors. Start with levothyroxine monotherapy at 1.6 mcg/kg/day. Recheck TSH at 6 weeks. This approach is endorsed by ATA, AACE, the British Thyroid Association, and the ETA. [1][2]

Situation 2: Optimized TSH on levothyroxine but persistent fatigue, brain fog, or low mood. Screen for non-thyroid causes first (iron deficiency, vitamin D deficiency, depression, sleep apnea). If those are excluded and free T3 is in the lower quartile of the reference range, a trial of low-dose liothyronine added to a reduced levothyroxine dose is reasonable, with TSH and free T3 rechecked at 6 weeks. The ETA 2019 guidance supports this as a Category B recommendation. [2]

Situation 3: Patient requests DTE or has previously felt better on it. DTE is a legitimate option for patients who have tried and not responded to T4 monotherapy, provided they understand the less certain evidence base, the fixed T4:T3 ratio, and supply-chain risks. Monitor both TSH and free T3. [8]

Situation 4: Malabsorption, GI disease, or high pill burden. Tirosint-SOL (liquid levothyroxine) reduces absorption variability. A dose change should still be followed by a 6-week TSH recheck. [5][6]

Levothyroxine Side Effects, Drug Interactions, and Contraindications

At properly titrated doses, levothyroxine side effects are primarily those of over-replacement (iatrogenic hyperthyroidism): palpitations, heat intolerance, tremor, insomnia, and weight loss. The 2015 AACE/ATA thyroid nodule guidelines note that TSH suppression below 0.1 mIU/L over years is associated with increased risk of atrial fibrillation and reduced bone mineral density in postmenopausal women. [11]

Several common drugs and supplements reduce levothyroxine absorption or accelerate its clearance:

• Calcium carbonate and calcium citrate supplements: separate by at least 4 hours. [1]
• Ferrous sulfate (iron): separate by at least 4 hours. [1]
• Proton pump inhibitors: reduce gastric acid and may impair tablet dissolution; consider Tirosint in long-term PPI users.
• Cholestyramine and colestipol: bind levothyroxine in the gut; separate by 4 to 5 hours.
• Rifampin, phenytoin, carbamazepine: induce hepatic metabolism and can raise levothyroxine requirements by 20 to 50%.

Levothyroxine is Pregnancy Category A (the FDA removed the letter categories in 2015, but historical data support its safety in pregnancy). Untreated hypothyroidism during pregnancy carries substantially higher risk than treated hypothyroidism, including increased rates of miscarriage, preterm birth, and impaired fetal neurodevelopment. [12]

How to Take Levothyroxine for Maximum Absorption

The standard recommendation is to take levothyroxine on an empty stomach, 30 to 60 minutes before the first meal of the day, with a full glass of water. [1] Some patients prefer bedtime dosing, and a 2007 randomized trial by Bolk et al. (N=90, published in Archives of Internal Medicine) found bedtime levothyroxine produced TSH reduction equivalent to morning dosing with slightly better free T4 levels, suggesting at least equivalent absorption. [13]

Coffee (including espresso) meaningfully delays levothyroxine absorption. A study in Thyroid (2008) showed that drinking coffee simultaneously with levothyroxine raised TSH by a mean of 0.45 mIU/L compared to water ingestion in the same patients. [14] Patients who cannot wait 30 to 60 minutes before coffee should consider switching to Tirosint-SOL, which shows less susceptibility to food-related interference.

Subclinical Hypothyroidism: Does Everyone Need Treatment?

Subclinical hypothyroidism (SCH) is defined as an elevated TSH (typically above 4.5 mIU/L) with normal free T4 and absent or minimal symptoms. Whether to treat is genuinely contested. [15]

The 2017 JAMA Internal Medicine TRUST trial (N=737, age 65 and older) found that levothyroxine for SCH produced no benefit over placebo on the Hypothyroid Symptom Score at 1 year. [15] That trial enrolled a predominantly older population; results may not generalize to younger patients or those with TSH above 10 mIU/L.

Current guidance from the ATA suggests treatment is reasonable for patients with TSH above 10 mIU/L regardless of symptoms, for pregnant women with TSH above trimester-specific thresholds, and for younger adults with clear symptoms. [1] Watchful waiting with repeat TSH in 3 to 6 months is appropriate for TSH between 4.5 and 10 mIU/L in asymptomatic adults over 65. [15]

Hashimoto Thyroiditis and Autoimmune Hypothyroidism

Hashimoto thyroiditis (chronic autoimmune thyroiditis) is the most common cause of hypothyroidism in iodine-sufficient regions, affecting an estimated 5% of the US population. [16] Thyroid peroxidase antibodies (TPO-Ab) are elevated in more than 90% of affected patients.

Levothyroxine is the treatment of choice once TSH rises above the normal range. The drug does not treat the underlying autoimmune process. TPO-Ab titers may decline over time on levothyroxine, but the 2014 ATA guidelines note this is not a primary treatment goal. [1]

Patients with Hashimoto thyroiditis and normal TSH who have significant symptoms deserve evaluation for conditions that frequently co-occur: celiac disease, adrenal insufficiency (Addison disease shares autoimmune pathways), and type 1 diabetes. These are not treated by levothyroxine, and missing them explains persistent symptoms despite euthyroid TSH.

Thyroid Cancer and TSH Suppression Therapy

After thyroidectomy for well-differentiated papillary or follicular thyroid cancer, levothyroxine serves a second role: suppressing TSH to reduce the stimulus for residual thyroid tissue (or micrometastases) to proliferate. TSH suppression targets depend on cancer risk stratification. [17]

The 2015 ATA thyroid cancer guidelines (Haugen et al.) define three tiers. High-risk patients (gross extrathyroidal extension, incomplete resection, distant metastases) target TSH below 0.1 mIU/L. Intermediate-risk patients target TSH between 0.1 and 0.5 mIU/L. Low-risk patients who are in remission can be maintained at TSH in the low-normal range (0.5 to 2.0 mIU/L) to minimize bone and cardiac side effects of prolonged suppression. [17]

Doses required for suppression are typically higher than full replacement, sometimes exceeding 2.0 to 2.2 mcg/kg/day. Bone mineral density should be monitored annually with DEXA scanning in postmenopausal women on suppressive therapy.